Whitehawk Therapeutics Inc. (WHWK) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.12 (-3.70% 1D, market cap $177.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, WHWK ranks #939 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $175.1M) and UPB (Upstream Bio Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $183.5M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while WHWK leads on capital efficiency (-35.0% ROIC).
Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 39.2 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While WHWK currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($3.28) forces dealer call-delta covering toward $5.76.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Whitehawk Therapeutics Inc. (WHWK) dropped -3.70% to $3.12, trading at 33% of its 52-week range ($1.97 – $5.49). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -72.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on WHWK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for WHWK. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Whitehawk Therapeutics Inc. (WHWK) ranks #939 by composite RQD confidence (24/100, grade E) and #587 by equity capitalization ($177.9M). Within this direct 5-issuer industry benchmark cohort, WHWK leads on earnings valuation at N/A trailing P/E, while WHWK leads on capital efficiency and profitability with -35.0% ROIC and 89.4% gross margin. ALXO currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with WHWK at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| WHWK
ACTIVE
Whitehawk Therapeutics Inc. | E | 24/100 | — | 89.4% | -35.0% | -3.70% | $177.9M | Benchmark Subject |
| ZNTL Zentalis Pharmaceuticals Inc. | E | 34/100 | — | — | -35.0% | -5.61% | $175.1M | /zntl-vs-whwk → |
| UPB Upstream Bio Inc. | E | 29/100 | — | — | -35.0% | -1.76% | $183.5M | /upb-vs-whwk → |
| ALXO ALX Oncology Holdings Inc. | D | 44/100 | — | — | -35.0% | +12.30% | $171.1M | /alxo-vs-whwk → |
| BBOT BridgeBio Oncology Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -11.83% | $185.2M | /bbot-vs-whwk → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported GAAP revenue of $7.1M (-72.5% vs. FY2024 revenue of $26.0M , and -70.7% cumulative change since FY2023) , GAAP net income of -$20.6M, operating cash flow of -$97.4M, and free cash flow of -$98.0M (-60.1% YoY). On the balance sheet, WHWK closed FY2025 with $150.8M in total assets against $0 in total debt (Altman Z-Score: 3.11, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.1M | -$20.6M | -$97.4M | -$98.0M | $150.8M | — |
| FY2024 (FY) | 2024-12-31 | $26.0M | -$63.7M | -$59.5M | -$61.2M | $70.3M | — |
| FY2023 (FY) | 2023-12-31 | $24.4M | -$65.8M | -$59.7M | -$59.7M | — | — |
As of 2026-11-03, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.12 (-3.70% 1D, market cap $177.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, WHWK ranks #939 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $175.1M) and UPB (Upstream Bio Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $183.5M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while WHWK leads on capital efficiency (-35.0% ROIC).
Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
WHWK last traded at $3.12 (-3.70% on volume of 216,121 shares), positioning the stock -17.89% below its 50-day simple moving average ($3.80) and -18.75% below its 200-day simple moving average ($3.84). Across its 52-week range of $1.97 to $5.49, WHWK sits at the 32.7% percentile with a 14-day RSI of 39.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.73 to $3.51).
Whitehawk Therapeutics Inc. (WHWK) earns a live Roarable RQD composite score of 24/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.12 (-3.70% 1D, market capitalization $177.9M).
Whitehawk Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. FY 2025 revenue was $7.1M, down from $26.0M in FY 2024.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported $7.1M in annual revenue (up from $26.0M in FY2024, -72.5% YoY) and -$20.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.4M revenue, -$65.8M net income) through FY2025, WHWK scaled operating cash flow to -$97.4M and free cash flow to -$98.0M, backed by $150.8M in total assets against $0 in total debt.
Supply_chain is NONE and butterfly_links is empty. The source data contains no upstream or downstream dependencies, sector correlation mapping, or bottleneck analysis. A prospective investor should note that the graph cannot identify second-order ripples from this data alone.
Real-time company headlines, analyst actions, and sector developments for Whitehawk Therapeutics Inc. (WHWK) • Click "Debate This Headline" to argue it in the Roar Pit below
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Long WHWK at $3.24 targeting $3.89. Per the market data, gross margin of 89.4% indicates high revenue-level economics if operating costs can be reduced.. Institutional whale score is 4/20 and the risk/reward vs. the $1.97 52-week low is skewed heavily in favor of bulls.
@RiskArb_Desk Shorting a 4/20 institutional whale-flow stock at $3.24 is dangerous when funds are rotating into Health Care.
I respect the product at Whitehawk Therapeutics Inc., but the stock at $3.24 is a different story. Per the SEC financials, free cash flow was negative in every reported period, with FY 2025 FCF at -$98.0M against $37.6M of cash.. FCF yield is 0.0% and RQD sits at 24/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: